Ultrasonographic Evaluation of the Change in Uterine Fibroids Induced by Treatment with a Gnrh Analog  by Chia, Chun-Chieh et al.
Taiwanese J Obstet Gynecol • June 2006 • Vol 45 • No 2124
Introduction
Uterine fibroids are the most common benign gyneco-
logic tumor and account for more than 80% of gyneco-
logic operations. To preserve the uterus, a combination
of medical and surgical management was created such
as GnRH analog (GnRHa) treatment before the opera-
tion. The aim of this prospective study was to deter-
mine the effects of GnRHa on uterine fibroids, as well
as on other new parameters including vascularity, for
the evaluation and management of fibroids. From these
results, we evaluated the possible mechanisms causing
fibroid shrinkage.
Materials and Methods
We chose 25 patients who had uterine fibroids, with
or without clinical symptoms and signs, for this prospec-
tive study. Each of them received 3D power Doppler
ultrasound (MEDISON 530D, Korea) before medica-
tion and surgery for the following parameters: for
fibroids, the size, volume, and blood flow patterns 
on the histogram including the vascularization index
(VI), flow index (FI), and vascularization–flow index
(VFI) were evaluated; and for the uterus, uterine arte-
rial blood flow as indicated by the pulsative index (PI)
and resistance index (RI) was determined. The VI was
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calculated as color voxels/(total voxels – background
voxels), the FI as weighted color voxels/(color voxels –
border voxels) and the VFI was calculated as weighted
color voxels/(total voxels – background voxels).
Two consecutive doses, 4 weeks apart, of a subcuta-
neous injection of 3.75 mg Leuplin depot (GnRHa,
Takeda, Taiwan) were given to the patients before 
surgery (a myomectomy). An ultrasound analysis was
performed on each patient according to the follow-
ing schedule: (a) before each injection, (b) before 
surgery, and (c) 3 consecutive months after surgery. In
addition, the total blood loss during the operation
was recorded.
Results
In total, 25 patients were involved in this study, but four
were lost to follow-up by the end of the study. All the
remaining patients (n21) received ultrasound before
each injection, before the operation, and for 3 consecu-
tive months after the operation. The mean age of the
patients was 34.8 (range, 27–45) years; the mean
decrease in fibroid volume, 68.3 mm3 (p0.014); mean
decrease in uterine volume, 97.3 mm3 (p0.037);
mean difference in PI, 0.19 (p0.43); mean difference
in RI, 0.01 (p0.87); mean difference in VI, –4.05
(p0.09); mean difference in FI, –2.42 (p0.36);
and the mean difference in VFI was –4.36 (p0.04).
The data indicated a significant decrease in uterine
volume (p0.039), fibroid volume (p0.014) (Table
1), and VFI (p0.049) (Table 2); VI and FI (Table 2)
seemed to decrease after GnRHa injection but not 
significantly, and RI and PI (Table 3) showed no 
difference after GnRHa injection.
Discussion
Uterine fibroids are the most common benign neo-
plasm in the female pelvis and occur in 20–25% of
women of reproductive age. They arise mostly from the
smooth muscle and soft tissue of the uterine fundus
and corpus, but 3% arise from the cervix [1]. There are
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Table 1. Volume of uterine and fibroid by ultrasound before and after GnRHa treatment
Pre-vol (ut) Post-vol (ut) Diff. ut Pre-vol (F) Post-vol (F) Diff. F
281.4 208.6 –72.8 143.8 124.7 –19.1
449.1 256.8 –192.9 295.9 109.0 –186.9
158.7 106.9 –51.8 29.5 10.8 –18.7
561.3 430.9 –130.4 193.0 212.3 19.3
189.1 195.8 6.7 98.8 126.9 28.1
372.9 357.3 –15.6 178.4 139.8 –38.6
481.5 309.7 –171.8 329.0 176.7 –152.3
169.7 139.7 –30.0 29.0 27.4 –1.6
757.5 598.7 –158.8 479.8 335.6 –144.2
355.3 364.4 9.1 214.2 165.1 –49.1
201.4 111.0 –90.4 134.6 21.3 –113.3
363.1 363.5 0.4 269.6 280.7 11.1
167.6 133.0 –34.6 181.9 82.3 –99.6
787.6 859.3 71.7 450.8 542.7 91.9
351.2 147.1 –204.0 56.6 40.4 –16.2
1,613.7 721.5 –892.2 829.7 363.2 –466.5
303.3 289.3 –14.0 208.7 150.3 –58.5
236.5 208.5 –27.9 102.9 107.1 4.3
298.8 371.1 72.3 166.0 181.3 15.3
971.9 990.3 18.3 882.1 709.6 –172.5
245.7 111.2 –134.5 126.2 59.0 –67.1
Mean — –97.3 — — –68.3
SD ratio — 199.5 — — 117.0
p — 0.04 — — 0.014
Pre-vol (ut)pretreatment uterine volume; Post-vol (ut)posttreatment uterine volume; Diff. utdifference in uter-
ine volume before and after treatment; Pre-vol (F)pretreatment fibroid volume; Post-vol (F)posttreatment fibroid 
volume; Diff. Fdifference in fibroid volume before and after treatment.
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various medical methods of management such as
GnRHa, progesterone, and danazol, and surgical meth-
ods such as a hysterectomy, myomectomy, and uterine
arterial obliteration. The study we designed here attem-
pted to evaluate the response of several aspects of
fibroids, especially the vascularity, to GnRHa treatment.
There are several effects of GnRHa on fibroids.
Histologically, the arterioles in the myomas have sig-
nificantly thicker walls, which is due to smooth muscle
cell hyperplasia in the muscularis media, and this
might play a role in the decreased blood flow [2].
Intramyomatous arteries are smaller and more often
show arteriosclerotic changes in leiomyomas removed
from women treated with GnRHa. Estrogen depriva-
tion induced by GnRHa may cause relative vasocon-
striction of the myomatous vessels. Increased cellularity
and hyalinization in leiomyomata were noted follow-
ing GnRH agonist treatment. GnRHa therapy sup-
presses cell proliferation and causes a transient increase
in apoptosis in uterine leiomyomas [3]. In addition, the
cellular proliferation index, ER, PR expression and the
number of cycling cells decrease, and there is a relative
overexpression of both collagen type I and collagen
type III mRNA [4].
The vascularization on the periphery of the myoma
with an RI value of 0.54 ± 0.08 was more clearly delin-
eated, but other myomas with necrosis, inflammation,
and degenerative change will give lower RI values. In
addition, the uterine arteries in those with a myoma
showed a lower impedance (RI of 0.74 ± 0.09) than the
ones without a myoma (RI of 0.84 ± 0.09) [5]. From
the view of 3D power Doppler, regular vascularity at
the periphery could be detected in 84.3% of myomas
[6]. Another new method of vascular quantification
called a 3D histogram was reported recently. It measures
the color percentage and flow amplitudes in the volume
of interest. Artifacts are rather common such as tissue,
patient, or probe movements because of the high 
sensitivity of the amplitude-based color Doppler. The
parameters of 3D histograms are the VI, FI, VFI, and
flow-vessel quotient (FVQ). These parameters provide
values for the vessels and the intensity of flow in the
tumor or tissue [7].
If the treated leiomyomata are not immediately
removed surgically after therapy, rapid regrowth can
occur and again cause clinical symptoms. The volume
of fibroids will shrink from 30% to 40% after 2–3 doses
of GnRHa, but can rebound to the same volume or
Table 2. Comparison of variables between VI, FI and VFI in fibroids
Pre-VI Post-VI Diff. VI Pre-FI Post-FI Diff. FI Pre-VFI Post-VFI Diff. VFI
0.01 0.05 0.05 37.60 57.60 20.00 0.002 0.03 0.03
25.80 0.70 –25.09 68.70 41.73 –26.90 17.70 0.29 17.40
3.00 2.50 –0.51 43.00 60.48 17.48 32.90 1.56 –31.30
1.60 0.78 –0.79 69.23 66.65 –2.58 1.09 0.52 –0.57
1.60 1.08 –0.54 64.60 61.78 –2.83 1.05 0.66 –0.39
4.17 1.09 –3.08 74.60 70.60 –4.01 3.11 0.77 –2.34
3.28 1.01 –2.27 70.47 67.10 –3.38 2.31 0.68 –1.63
8.38 21.35 12.97 69.92 71.00 1.10 5.85 15.16 9.31
4.14 4.92 0.78 65.05 57.70 –7.30 2.69 2.84 0.15
8.42 13.94 5.52 68.10 65.38 –2.72 5.73 9.10 3.38 
17.13 1.37 –15.76 66.34 65.88 –0.46 11.36 0.90 –10.46
15.40 0.35 –15.05 68.23 59.13 –9.10 10.50 0.21 –10.29
19.00 0.73 –18.27 70.00 63.65 –6.35 13.30 0.46 –12.84
22.70 1.45 –21.25 74.30 46.70 –27.60 16.90 0.67 –16.23
11.90 0.53 –11.37 59.63 66.88 7.25 7.15 0.35 –6.80
0.61 2.84 2.23 533.88 63.00 9.15 0.33 1.79 1.46
0.28 12.42 12.14 61.73 61.70 –0.01 0.17 7.66 7.46
2.51 1.73 –0.78 66.35 47.30 –19.10 1.66 0.82 –0.84
0.53 1.65 1.12 64.51 66.30 1.82 0.35 1.09 0.74
8.70 15.90 7.20 69.82 69.36 –0.46 6.07 11.10 5.00
20.00 7.61 –12.39 68.85 74.16 5.31 13.70 5.64 –8.00
Mean — –4.05 — — 2.41 — — –4.36
SD ratio — 10.60 — — 12.89 — — 9.56
p — 0.09 — — 0.36 — — 0.05
VI color voxels/(total voxels – background voxels); FIweighted color voxels/(color voxels – border voxels); VFIweighted color voxels/(total voxels –
background voxels); Prepretreatment; Postposttreatment; Diff.differences.
larger within 2–3 months after cessation of the 
drug. From the aspect of vascularity, statistically 
significant increase in RI and PI for major leiomyoma
vessels were observed at the end of the 4th week, 
which further significantly increased after 8 and 12
weeks. These findings were directly correlated with 
significant decreases in estradiol levels after 4, 8, and
12 weeks [8].
The dosages and duration of GnRHa, according 
to the literature [9–11] and our own experiences showed
that the volume of the fibroids shrank dramatically
and that the total blood loss during the operation was
less after two doses of GnRHa injection. Therefore, 
we used two doses of 3.75 mg Leuplin depot (GnRHa)
1 month apart, as a subcutaneous injection in this
study. A myomectomy was performed 1 month after the
last dose. In addition, it was reported that the combi-
nation of GnRHa with raloxifene induced a higher
reduction in fibroid sizes.
Genetically, we used comparative genomic hybridiza-
tion (CGH) to evaluate the different effects of fibroid
shrinkage after GnRHa treatment. CGH can determine
the site of genomic instability (by defining specific
loci) and by utilizing results of the Human Genome
Project (DNA sequence) for microarray detection, we
were further able to detect the functional proteins
from gene expression. Medical treatment of a leiomy-
oma may soon exist through knowledge of the func-
tion of a particular protein’s expression pattern. Using
this knowledge for genetic consultations may be diffi-
cult, but it is encouraging and may provide a new way
to treat fibroids.
Conservative management of fibroids, which has
lower morbidity and mortality, is important especially in
patients who wish to retain the ability of child-bearing.
Therefore, this study provides more information about
the possible pathogenesis of leiomyomatous lesions
from the myometrium by vascularization and together
with information from CGH and the Human Genome
Project, a new modality of treatment for fibroids may be
possible.
From the various data shown in this study, the vol-
ume and vascularity of fibroids (including the VI, FI
and VFI), and the volume of the uterus decreased sig-
nificantly after two doses of GnRHa treatment. In
addition, blood loss during the operation decreased
significantly compared to that of an untreated group.
The quantitative values (including VI, FI and VFI) of
the 3D histogram did not significantly differ, possibly
due to the limited number of patients.
Taiwanese J Obstet Gynecol • June 2006 • Vol 45 • No 2 127
GnRHa and Fibroid Shrinkage
Table 3. Comparison of RI and PI values in uterine artery
Pre-RI Post-RI Diff. RI Pre-PI Post-PI Diff. PI
0.78 0.29 –0.49 1.61 3.19 1.58
0.12 1.00 0.88 5.40 5.50 0.10
0.44 0.25 –0.19 1.48 2.57 1.09
0.22 0.39 0.17 0.92 1.07 0.15
0.90 1.00 0.10 3.06 2.59 –0.47
0.71 0.59 –0.12 1.98 2.51 0.53
0.52 0.68 0.16 1.98 1.53 –0.45
0.67 0.61 –0.06 1.11 2.23 1.12
0.45 0.35 –0.10 1.20 2.78 1.58
0.78 1.00 0.22 2.15 2.77 0.62
0.74 0.44 –0.30 1.96 1.50 –0.46
0.14 0.64 0.50 0.96 2.96 2.00
0.67 0.45 –0.22 1.96 2.39 0.43
0.81 0.64 –0.17 2.46 1.17 –1.29
0.31 0.20 –0.11 1.15 0.98 –0.17
0.23 0.69 0.46 3.94 3.05 –0.89
0.38 0.29 –0.09 1.35 0.77 –0.58
0.88 0.86 –0.02 2.20 3.63 1.43
0.80 0.38 –0.42 4.55 2.43 –2.12
0.34 0.00 –0.34 1.11 0.00 –1.11
0.62 1.00 0.38 2.70 3.57 0.87
Mean — 0.01 — — 0.18
SD — 0.33 — — 0.08
p — 0.87 — — 0.43
RI resistance index; PIpulsative index.
Finally, the blood flow in the uterus and fibroids is
another important parameter with fibroid shrinkage,
and 3D histograms are a new and quantitative method
for blood flow detection that can be used preopera-
tively and for the conservative treatment of fibroids.
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